Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Barley (*Hordeum vulgare*) is a major cereal grain widely utilized as a food source and a dietary supplement for its metabolic and cardiovascular health benefits. Its primary therapeutic value is attributed to its high content of soluble fiber, particularly beta-glucans. These fibers form a viscous gel in the gastrointestinal tract, which delays gastric emptying and slows the absorption of dietary glucose, thereby improving postprandial glycemic control. Furthermore, barley beta-glucans bind to bile acids in the small intestine, promoting their excretion and forcing the liver to utilize circulating LDL cholesterol for new bile acid synthesis, effectively lowering blood cholesterol levels. Barley also contains bioactive alkaloids such as hordenine, which has been studied for its potential interaction with dopamine receptors and its role in metabolic regulation. The FDA has recognized the heart-health benefits of barley by allowing health claims regarding its ability to reduce the risk of coronary heart disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on barley.